[{"address1": "Semmelweisstrasse 7", "city": "Planegg", "zip": "82152", "country": "Germany", "phone": "49 89 899 27 0", "fax": "49 89 899 27 222", "website": "https://www.morphosys.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sj\u00f6gren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.", "fullTimeEmployees": 464, "companyOfficers": [{"maxAge": 1, "name": "Ms. Charlotte  Lohmann", "age": 53, "title": "Chief Legal and Human Resources Officer & Member of Management Board", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 517238, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arkadius  Pichota M.B.A., Ph.D.", "title": "Chief Executive Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lukas  Gilgen", "title": "Chief Financial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tim  Demuth M.D., Ph.D.", "age": 49, "title": "Chief Research & Development Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Klaus  De Wall", "title": "Head of Accounting & Tax", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Margit  Urban", "title": "Head of Discovery Alliances & Technologies", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julia  Neugebauer Ph.D.", "title": "Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Barbara  Krebs-Pohl Ph.D.", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. G\u00fcnter  Wellnhofer", "title": "Head of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harald  Watzka", "title": "Head of Alliance Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 6, "shareHolderRightsRisk": 6, "overallRisk": 6, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 18.51, "open": 18.518, "dayLow": 18.38, "dayHigh": 19.15, "regularMarketPreviousClose": 18.51, "regularMarketOpen": 18.518, "regularMarketDayLow": 18.38, "regularMarketDayHigh": 19.15, "beta": 0.662, "forwardPE": -6.362416, "volume": 19165, "regularMarketVolume": 19165, "averageVolume": 47073, "averageVolume10days": 8490, "averageDailyVolume10Day": 8490, "marketCap": 2856343040, "fiftyTwoWeekLow": 4.185, "fiftyTwoWeekHigh": 19.5, "priceToSalesTrailing12Months": 11.828911, "fiftyDayAverage": 18.4604, "twoHundredDayAverage": 14.735, "currency": "USD", "enterpriseValue": 1816648448, "profitMargins": -1.9060899, "floatShares": 225609, "sharesOutstanding": 150651008, "sharesShort": 262051, "sharesShortPriorMonth": 292866, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.00090000004, "heldPercentInstitutions": 0.074439995, "shortRatio": 2.65, "bookValue": -6.956, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -468573632, "trailingEps": -1.5, "forwardEps": -2.98, "enterpriseToRevenue": 7.523, "enterpriseToEbitda": -4.084, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MOR", "underlyingSymbol": "MOR", "shortName": "MorphoSys AG", "longName": "MorphoSys AG", "firstTradeDateEpochUtc": 1524144600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e69ac107-9473-3ee4-815d-c7bb67c1cad3", "gmtOffSetMilliseconds": -14400000, "currentPrice": 18.96, "targetHighPrice": 16.71, "targetLowPrice": 11.6, "targetMeanPrice": 14.16, "targetMedianPrice": 14.16, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 2, "totalCash": 630772608, "totalCashPerShare": 16.775, "ebitda": -444867104, "totalDebt": 1734497536, "quickRatio": 1.356, "currentRatio": 1.384, "totalRevenue": 241471344, "revenuePerShare": 1.71625, "returnOnAssets": -0.13838, "freeCashflow": 98898008, "operatingCashflow": -283926048, "revenueGrowth": 0.131, "grossMargins": 0.75094, "ebitdaMargins": -1.84232, "operatingMargins": -9.60145, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-08-26"}]